Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.77 |
| ▸ | CTSS | P25774 | 6/20 | 0.74 |
| ▸ | CTSL | P07711 | 2/20 | 0.74 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.74 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.74 |
| ▸ | CTSB | P07858 | 1/20 | 0.74 |
| ▸ | CA5A | P35218 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29052552 | 1.00 | CTSK (0.77) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL9115066 | 0.91 | CAPN1 (0.80) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL20542841 | 0.91 | CAPN1 (0.76) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL13870521 | 0.91 | CAPN1 (0.76) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL20542843 | 0.91 | CAPN1 (0.76) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL14067668 | 0.90 | CTSK (0.77) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL25287997 | 0.89 | CTSK (0.74) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL25245595 | 0.89 | CTSK (0.74) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL10802560 | 0.88 | CTSL (0.73) | CTSKCTSSCTSLCAPN1CAPN2 | |
| SCHEMBL5443106 | 0.87 | CAPN1 (0.74) | CTSKCTSSCTSLCAPN1CAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4083051-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-114867734-A | Method for synthesizing peptide compound | 中外制药株式会社 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | VIP, NGLY1, NPPA | CTSK 214/4885CTSS 231/4885CTSL 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.